Timber Pharmaceuticals Inc

Timber Pharmaceuticals — Investor Presentation (February 2021)

22 slides from Timber Pharmaceuticals's investor presentation, Feb 4, 2021

  1. Slide 1: Building Bridges in Medical Dermatology

    Building Bridges in Medical Dermatology Investor Presentation NYSE American: TMBR February 2021

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward - looking s

  3. Slide 3: Timber Pharmaceuticals Overview

    3 Timber Pharmaceuticals Overview Timber Pharmaceuticals is building a rare and orphan dermatology company that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company’s investigational thera

  4. Slide 4: Investment Highlights

    4 Investment Highlights • Positioned to become a leading dermatology company with a focus on rare and orphan diseases, led by a management team with a pro ven track record in development and commercialization • High potential, late stage, lower risk multi - product candidate pipeline • Proven clinic

  5. Slide 5: Timber's Focused Strategy and Tactics

    5 Timber’s Focused Strategy and Tactics • Focus on mitigating the cost, risk, and time of drug development while retaining earnings potential • Based on three key tactics: • Emphasis on compounds with broad and proven mechanisms of action across many dermatologic conditions • Differentiation of the

  6. Slide 6: Timber Business Model

    6 Timber Business Model • Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Why Orphan Drugs? • Timber will be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires smaller and less costly drug trials with greater flexibility

  7. Slide 7: Rare dermatological diseases underrepresented in drug development

    7 • Rare dermatological diseases are underrepresented in drug development and pharmaceutical company sponsored trials • Approximately 30 million people in the U.S. are living with a rare disease – equivalent to 1 in 10 Americans • Many orphan and rare dermatology disorders are associated with signif

  8. Slide 8: Strategic Pipeline in Rare Dermatologic Disease

    8 Strategic Pipeline in Rare Dermatologic Disease NYSE American: TMBR SP4

  9. Slide 9: TMB-001 for Congenital Ichthyosis

    9 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis has a prevalence of 1:2,000 - 1:6,000 males • Lamellar Ichthyosis has a prevalence of 1:100,000 - 200,000 Quality of life is signif

  10. Slide 10: TMB-001 Topical Isotretinoin in CI

    10 Isotretinoin is widely viewed as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where high dose, chronic oral therapy cannot be tolerated due to systemic toxicity TMB - 001 utilizes patented IPEG™ delivery system to target isotretino

  11. Slide 11: TMB-002 for Facial Angiofibromas in Tuberous Sclerosis Complex

    11 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple

  12. Slide 12: TMB-002 Topical Rapamycin (Pascomer)

    12 TMB - 002 Topical Rapamycin (Pascomer®) Potentially the First Commercially Available, High - Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in preclinical toxicity studies Utilizes tr

  13. Slide 13: Barriers to Entry

    13 Barriers to Entry • Orphan exclusivity granted for all three strategic assets • 7 years in U.S., 10 years in E.U. • Patents granted and pending globally • Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidation, temperature sensitivities, stab

  14. Slide 14: TMB-003 Topical Sitaxsentan for Cutaneous Fibrosis

    14 TMB - 003 Topical Sitaxsentan for Cutaneous Fibrosis Highly Selective ET - A inhibitor Sitaxsentan was a highly selective (6,500:1) ET - A receptor antagonist previously on the market in the EU, Canada and Australia as an oral treatment for PAH, but voluntarily withdrawn from global market in 201

  15. Slide 15: Scleroderma

    15 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in the U.S. • Systemic s

  16. Slide 16: Life Cycle Management

    16 Life Cycle Management Market expansion potential for additional indications for all products Severe Acne Port Wine Stains Hypertrophic/Keloid Scars TMB - 001 TMB - 002 TMB - 003 Sturge - Weber Syndrome Darier’s Disease Scarring Alopecia Sebaceous Hyperplasia NYSE American: TMBR Rare Diseases High

  17. Slide 17: Significant Clinical Milestones over next 12 months

    17 Significant Clinical Milestones on a Quarterly Basis over next 12 months TMB - 001 TMB - 002 Q1 2021 Reach 50% enrollment of the Phase 2B trial Reach 50% enrollment of the Phase 2B trial Q2 2021 Complete enrollment Complete enrollment Receive 3 rd tranche of grant funding Q3 2021 Topline data for

  18. Slide 18: World Class Clinical Advisors and Partners

    18 World Class Clinical Advisors and Partners Clinical Advisors • Peter Elias, MD – Professor, Dept of Dermatology, University of California, San Francisco (UCSF) • Keith Choate, MD, PhD – Professor of Dermatology, Pathology, and Genetics, Yale University • Joyce Teng, MD – Professor and Director of

  19. Slide 19: Leadership Team

    19 Leadership Team Strong Balance between Entrepreneurial Acumen and Proven Operational Leadership Michael Derby, MS, MBA Executive Chairman • Pharma entrepreneur with several successful exits • Managing Partner of TardiMed Sciences • Founder of Norphan Pharmaceuticals, rare neurology drug developme

  20. Slide 20: Financial and Capitalization Highlights

    20 Financial and Capitalization Highlights On May 18, 2020, upon closing of its merger with a NYSE - listed company, Timber also completed a financing with gross proceeds of $25 million, which included the conversion of a $5 million bridge note previously issued by Timber and the issuance of Series

  21. Slide 21: Investment summary

    21 ▪ Topical Isotretinoin for Congenital Ichthyosis ▪ Topical Rapamycin for Facial Angiofibromas in Tuberous Sclerosis Complex ▪ Locally Delivered Endothelin - A Antagonist for Scleroderma ▪ Partnering opportunities for recently acquired non - strategic Topical Minocycline programs ▪ Track record of

  22. Slide 22: Building Bridges in Medical Dermatology - Contact

    Building Bridges in Medical Dermatology For additional Investor Information please contact: John Koconis Stephanie Prince CEO PCG Advisory jkoconis@timberpharma.com sprince@pcgadvisory.com (646) 863 - 6341 Thank You www.timberpharma.com

Timber Pharmaceuticals — Investor Presentation (February 2021) on 6ix